FDA Approves Gilead's Bixlenvo, the Smallest Single-Tablet HIV Regimen

The U.S. Food and Drug Administration approved Gilead's Bixlenvo, a once-daily tablet combining bictegravir, an integrase inhibitor, with lenacapavir, a capsid inhibitor, for adults living with HIV who are virologically suppressed but cannot take existing single-tablet regimens. Gilead positions Bixlenvo as the smallest single-tablet regimen available and the first option for patients on complex regimens limited by prior drug resistance or tolerability issues.

The Trial Evidence

The approval is based on the Phase III trials Artistry-1 and Artistry-2, which showed sustained viral suppression at week 48. One of the studies enrolled the oldest population in a Phase III HIV treatment registration trial to date, with a median age of 60 and a median treatment history of 28 years, demonstrating the therapy's fit for long-term survivors switching off complex regimens.

A Late-August Approval Wave

Bixlenvo is part of a flurry of FDA actions in late August, which also included the first targeted therapy for dermatomyositis, an expanded cardiovascular indication for a GLP-1 medicine, and a new COVID-19 vaccine. The cluster reflects a busy end-of-summer review cycle for the agency's Center for Drug Evaluation and Research.

Why It Matters

Simplifying HIV treatment to a single small tablet can improve adherence and quality of life for a population that has accumulated resistance to older drug classes over decades of therapy. For Gilead, Bixlenvo extends its dominance in HIV treatment and gives clinicians a switch option for patients whose current single-tablet therapies have failed or become burdensome.